{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:20:44Z","timestamp":1787246444015,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.biopha.2020.110444","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T08:53:01Z","timestamp":1592988781000},"page":"110444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma"],"prefix":"10.1016","volume":"129","author":[{"given":"Corrado","family":"Pelaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Busceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110444_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-020-00785-1","article-title":"Asthma epidemiology and risk factors","volume":"42","author":"Stern","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.biopha.2020.110444_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/879783","article-title":"Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma","author":"Pelaia","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.biopha.2020.110444_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101294","article-title":"Asthma from immune pathogenesis to precision medicine","volume":"46","author":"Khalaf","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/all.13966","article-title":"Different endotypes and phenotypes drive the heterogeneity in severe asthma","volume":"75","author":"McDowell","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.biopha.2020.110444_bib0025","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0030","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0035","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"SANI network, the severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.biopha.2020.110444_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/jir.2019.0180","article-title":"The involvement of type 2 innate lymphoid cells in airway inflammation in asthma","volume":"40","author":"Shi","year":"2020","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.biopha.2020.110444_bib0050","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2020.110444_bib0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","article-title":"Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma","volume":"116","author":"Tran","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0060","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fimmu.2014.00234","article-title":"Immune responses to inhalant mammalian allergens","volume":"5","author":"Hentges","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0065","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1183\/13993003.01824-2014","article-title":"Asthma phenotypes and IgE responses","volume":"47","author":"Froidure","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2020.110444_bib0070","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201910-1934CI","article-title":"Optimal asthma control: time for a new target","author":"Beasley","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14712598.2018.1402003","article-title":"Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children","volume":"18","author":"Pelaia","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2020.110444_bib0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2020.110444_bib0085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01167-2017","article-title":"Asthma and corticosteroids: time for a more precise approach to treatment","volume":"49","author":"Dunican","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2020.110444_bib0090","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","article-title":"Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease","volume":"131","author":"Barnes","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0095","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17476348.2020.1735365","article-title":"Clinical relevance of understanding mitogen-activated protein kinases involved in asthma","volume":"14","author":"Pelaia","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0100","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a european respiratory Society\/American thoracic society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2020.110444_bib0105","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of asthma: more than a decade of real life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.biopha.2020.110444_bib0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pupt.2018.11.002","article-title":"Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: results of a 5-year single-centre observational study","volume":"54","author":"Pelaia","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.110444_bib0115","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","article-title":"Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.biopha.2020.110444_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.110444_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101899","article-title":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","volume":"61","author":"Sposato","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.110444_bib0130","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/TCRM.S111862","article-title":"Role of biologics in severe eosinophilic asthma - focus on reslizumab","volume":"12","author":"Pelaia","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.biopha.2020.110444_bib0135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/DDDT.S155307","article-title":"Benralizumab in the treatment of severe asthma: design, development and potential place in therapy","volume":"21","author":"Pelaia","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.biopha.2020.110444_bib0140","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","author":"Pelaia","year":"2018","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.biopha.2020.110444_bib0145","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/14712598.2017.1387245","article-title":"Dupilumab for the treatment of asthma","volume":"17","author":"Pelaia","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2020.110444_bib0150","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2020.110444_bib0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/17476348.2020.1718495","article-title":"Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab","volume":"14","author":"Hillas","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0160","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0165","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110444_bib0170","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110444_bib0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2222.2008.03157.x","article-title":"Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype","volume":"39","author":"Dougherty","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.biopha.2020.110444_bib0180","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2020.110444_bib0185","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201107-1317PP","article-title":"Severe asthma \u2013 lessons learned from the National Heart, Lung, and Blood Institute severe asthma research program","volume":"185","author":"Jarjour","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/JAA.S240044","article-title":"Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma. Phase IIIb randomized, controlled trial (SOLANA)","volume":"13","author":"Panettieri","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.biopha.2020.110444_bib0195","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101830","article-title":"Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose","volume":"58","author":"Pelaia","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2020.110444_bib0205","article-title":"Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma","volume":"8","author":"Pelaia","year":"2020","journal-title":"SAGE Open Med. Case Rep."},{"key":"10.1016\/j.biopha.2020.110444_bib0210","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma \u2013 clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0220","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0225","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.biopha.2020.110444_bib0230","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaip.2016.07.015","article-title":"Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study","volume":"5","author":"Zeiger","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.biopha.2020.110444_bib0235","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0240","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0245","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1183\/09031936.97.10020292","article-title":"The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics","volume":"10","author":"Carroll","year":"1997","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2020.110444_bib0250","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1164\/ajrccm.158.2.9705036","article-title":"Inflammatory cell distribution within and along asthmatic airways","volume":"158","author":"Haley","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0255","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/cea.13465","article-title":"Blood eosinophil count correlates with severity of respiratory failure in life-threatening asthma and predicts risk of subsequent exacerbations","volume":"49","author":"Yii","year":"2019","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.biopha.2020.110444_bib0260","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.coi.2007.07.021","article-title":"The role of eosinophils in airway tissue remodeling in asthma","volume":"19","author":"Kariyawasam","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101346","article-title":"Immune induction of airway remodeling","volume":"46","author":"Guida","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0270","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.it.2004.07.006","article-title":"A role for eosinophils in airway remodelling in asthma","volume":"25","author":"Kay","year":"2004","journal-title":"Trends Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2020.110444_bib0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1752-699X.2010.00192.x","article-title":"The eosinophil and airway remodelling in asthma","volume":"4","author":"Venge","year":"2010","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.biopha.2020.110444_bib0280","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0285","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The asthma control test and the asthma control questionnaire for assessing asthma control: systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105819","article-title":"Eosinophils, the IL-5\/IL-5R \u03b1 axis, and the biologic effects of benralizumab in severe asthma","volume":"160","author":"Matucci","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.biopha.2020.110444_bib0295","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MOH.0b013e328331fae9","article-title":"Role of interleukins in the regulation of basophil development and secretion","volume":"17","author":"Valent","year":"2010","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.biopha.2020.110444_bib0300","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor \u03b1 mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0305","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","article-title":"Immunological decision-making: how does the immune system decide to mount a helper T-cell response?","volume":"123","author":"Kaiko","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2020.110444_bib0310","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jaci.2016.06.032","article-title":"Human circulating group 2 innate lymphoid cells can express CD154 and promote IgE production","volume":"139","author":"Maggi","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2020.110444_bib0315","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.alit.2018.11.001","article-title":"Airway innate lymphoid cells in the induction and regulation of allergy","volume":"68","author":"Doherty","year":"2019","journal-title":"Allergol. Int."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220306375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220306375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:06:42Z","timestamp":1760098002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220306375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":63,"alternative-id":["S0753332220306375"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110444","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110444"}}